

ASX ANNOUNCEMENT

1 April 2026

Little Green Pharma Ltd (ASX: LGP)

DISPATCH OF SUPPLEMENTARY SCHEME BOOKLET



Little Green Pharma Ltd (ASX:LGP) (**LGP** or the **Company**) refers to the Company's proposed acquisition of 100% of the issued capital of Cannatrek Ltd (**Cannatrek**) by way of scheme of arrangement under Part 5.1 of the Corporations Act 2001 (Cth) (**Corporations Act**) (**Scheme**).

LGP is pleased to announce the dispatch of the supplementary explanatory statement to Cannatrek Shareholders today providing additional information about the Scheme (**Supplementary Scheme Booklet**).¹

Capitalised terms used in this announcement have the meaning given to them in the Scheme Booklet, unless otherwise specified.

DISPATCH OF THE SUPPLEMENTARY SCHEME BOOKLET

Cannatrek has completed the dispatch of the Supplementary Scheme Booklet, which was sent to Cannatrek Shareholders as follows:

1. Cannatrek Shareholders who have an email address on record or who have previously elected to receive communications electronically (**Email Members**) have been sent an email which contains instructions about how to access an electronic copy of the Supplementary Scheme Booklet; and
2. Cannatrek Shareholders who are not Email Members have been sent a printed copy of the Supplementary Scheme Booklet by post.

The Supplementary Scheme Booklet is available for viewing and downloading on LGP's website at <https://investlittlegreenpharma.com/site/content/> and on LGP's ASX market announcements platform at <https://www.asx.com.au/>.

¹ Refer to LGP's ASX announcement "Supplementary Scheme Booklet" dated 1 April 2026.

Cannatrek Shareholders should read and consider both the Scheme Booklet dated 4 March 2026 and the Supplementary Scheme Booklet, including the materials accompanying them, before deciding how to vote at the Scheme Meeting. The Scheme Booklet includes important information including the reasons why Cannatrek Shareholders may wish to vote in favour of or against the Scheme Resolution, and details regarding LGP’s intentions in respect of Cannatrek from implementation of the Scheme (including key risks).

Further information on how Cannatrek Shareholders can participate and vote at the Scheme Meeting, or lodge a proxy form, will be provided in the Notice of Scheme Meeting, included in the Scheme Booklet.

INDEPENDENT EXPERT’S REPORT

The Scheme Booklet includes (as Annexure 2 to the Scheme Booklet) a copy of the Independent Expert’s Report prepared by RSM Corporate Australia Pty Ltd (Independent Expert). The Independent Expert has concluded that the Scheme is fair and reasonable and that the Scheme is in the best interests of Cannatrek Shareholders, in the absence of a Superior Proposal.

The Independent Expert's conclusion should be read in context with the full Independent Expert's Report, the Scheme Booklet and the Supplementary Scheme Booklet, which, in addition to other information, detail the reasons why the Independent Expert reached this conclusion.

It should be noted that the additional information contained in the Supplementary Scheme Booklet has not resulted in any change to the opinion given in the Independent Expert.

BOARD RECOMMENDATIONS AND VOTING INTENTIONS

The Cannatrek Board has unanimously recommended that Cannatrek Shareholders vote in favour of the Scheme, in the absence of a Superior Proposal and subject to the Independent Expert concluding (and continuing to conclude) that the Scheme is in the best interests of Cannatrek Shareholders. Subject to those same qualifications, each Cannatrek Director intends to vote (or procure the voting of) all Cannatrek Shares held or controlled by them at the time of the Scheme Meeting in favour of the Scheme.

The LGP Board unanimously recommends that LGP Shareholders vote in favour of the LGP Resolutions that are contained in the LGP Notice of Meeting, in the absence of a LGP Superior Proposal. Each LGP Director will, in the absence of a LGP Superior Proposal, vote (or procure the voting of) all LGP Shares held or controlled by them at the time of the LGP Shareholder Meeting in favour of the LGP Resolutions.



This announcement has been authorised for release by the board of Little Green Pharma Ltd

For further information please contact:

**Alistair Warren
Company Secretary**

Little Green Pharma
E: cosec@lgp.global
T: +618 6280 0050

**Paul Long
Managing Director**

Little Green Pharma
E: p.long@lgp.global
T: +618 6280 0050



About Little Green Pharma

Little Green Pharma Ltd (ASX:LGP) is a leading global medicinal cannabis company with vertically integrated operations across Europe and Australia.

LGP has a diverse and growing portfolio of cannabis-based medicines, distributed across Australia and over 12 export markets via a network of wholesalers, pharmacies, clinics, and GPs. The Company generates revenue through both the sale of medicinal cannabis products and its domestic Health House distribution business, which allows it to capture value across the supply chain and to adapt to evolving regulatory environments while building defensible commercial positions in high-growth markets.

Operating three production facilities in Denmark and Australia – including the largest facility in Europe – LGP is the one of the top three suppliers in Australia, the largest supplier into France, and a significant supplier into Germany and the UK, positioning it as a key player in global medicinal cannabis markets.

With diversified revenue streams, a presence in over a dozen export markets, and a high net tangible asset position relative to its enterprise value, LGP offers investors leveraged exposure to global medicinal cannabis demand and a clear platform for scalable growth.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email to help reduce our costs and environmental footprint.

To easily update your communication preferences, visit:
www.computershare.com.au/easyupdate/lgp